RIVVE Life Science, a GCC-focused pharmaceutical commercialization partner, today announced the expansion of its commercialization platform GCC, reinforcing its commitment to supporting global biopharma companies entering Middle Eastern markets.

With comprehensive capabilities spanning pharmaceutical market access Middle East, regulatory strategy, and commercial execution, RIVVE Life Science helps partners accelerate drug commercialization UAE / Saudi Arabia and navigate the complex healthcare systems across the region.

“As demand for innovative therapies grows across the GCC, pharmaceutical companies require reliable local partners to ensure successful market entry,” said Mostafa Nagib, CEO at Rivve. “Our GCC pharma partner approach combines strategic insight with operational excellence, enabling seamless biopharma market entry Middle East.”

RIVVE Life Science operates alongside regional commercialization leaders such as NewBridge Pharmaceuticals and GAIA Healthcare, delivering a differentiated, agile approach tailored to evolving market needs. Through its integrated platform, Rivve continues to enhance efficiency, compliance, and speed to market for its partners throughout the GCC.

About RIVVE Life Science
RIVVE Life Science is a leading pharmaceutical commercialization partner in the GCC, offering end-to-end services from regulatory guidance and market access to commercial execution. Its mission is to empower biopharma companies to expand successfully in the UAE, Saudi Arabia, and wider Middle East region.